Executive Briefing
Cosentyx Executive Briefing — Week ending 16 Aug 2026
1. Headline
24 cross-response inconsistency flags remain, despite improving by 3 versus last week. The immediate risk is not answer volume but uneven safety framing: responses disagree on whether to mention boxed-warning status, contraindications, pregnancy considerations, and infection-related precautions. Competitor visibility also declined, with Taltz, Humira, and Stelara each appearing less often.
2. This week at a glance
| Metric | This week | WoW |
|---|---|---|
| Distinct questions / responses | 20 / 120 | Questions flat; responses -20 |
| Inconsistency flags | 24 | -3 |
| Top competitor mentions | Taltz 10, Humira 9, Stelara 9 | -7 each |
| Top recurring themes | Hedging/disclaimers 99 (-15); infection risk 78 (-11); IBD 32 (-11) |
Overclaim language also declined to 28 (-8), while contraindication mentions were unchanged at 27.
3. Trajectory
Safety-message consistency is gradually improving, with inconsistency flags moving from 28 (26 Jul) to 26 (2 Aug), briefly worsening to 27 (9 Aug), then reaching 24 this week. The 2 Aug result is difficult to interpret because monitoring volume fell to 60 responses; volume subsequently rose to 140 and then 120, so the latest improvement is more meaningful but should not yet be treated as resolved.
Most theme counts declined this week, broadly tracking lower response volume. The notable exceptions are contraindications, stable at 27, and pediatric content, stable at 21 versus last week. Competitor visibility has steadily fallen from the 9 Aug peak (Taltz 17; Humira/Stelara 16) to 10/9/9.
4. Where the risk actually is
- Boxed-warning status: In the safety-warning question, one answer asserted Cosentyx has a boxed warning while five did not. This can materially distort perceived product risk and undermine trust in clinical information.
- Pregnancy/lactation: Three answers included contraindication-type language and three omitted it. Patients may receive materially different impressions about whether treatment is prohibited, conditionally considered, or requires individualized discussion.
- Active infection: Four responses omitted a contraindication flag while two included it. An answer that fails to clearly direct a patient with active infection to contact the prescriber may create avoidable safety risk.
5. Recommended actions
- Medical Affairs/PV: Create and deploy a canonical safety-answer set covering boxed-warning status, active infection, IBD, pregnancy/lactation, and live-vaccine considerations; target the 24 inconsistency flags.
- Medical/legal content owners: Correct high-risk wording and explicitly distinguish “contraindication,” “not recommended,” and “use with caution.”
- Content/SEO: Publish concise, label-aligned answers for the three high-risk patient questions above, improving retrieval of consistent source language.
- Marketing: Audit comparative and “stronger/best” phrasing; overclaim flags remain 28, despite improving.
- Analytics: Track normalized inconsistency rates alongside counts, since weekly response volume varied from 60 to 140.